EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody

Noriyuki Nishiwaki, Kazuhiro Noma, Toshiaki Ohara, Tomoyoshi Kunitomo, Kento Kawasaki, Masaaki Akai, Teruki Kobayashi, Toru Narusaka, Hajime Kashima, Hiroaki Sato, Satoshi Komoto, Takuya Kato und 6 weitere

Cancer Immunology, Immunotherapy · 2023-07 · 72 (7) · 2029-2044

DOI: 10.1007/s00262-023-03378-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 10.02.2023. Verfasst von Noriyuki Nishiwaki und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-Cho,…. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Okayama University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-associated fibroblasts (CAFs) are a critical component of the tumor microenvironment and play a central role in tumor progression. Previously, we reported that CAFs might induce tumor immunosuppression via interleukin-6 (IL-6) and promote tumor progression by blocking local IL-6 in the tumor microenvironment with neutralizing antibody. Here, we explore whether an anti-IL-6 receptor antibody could be used as systemic therapy to treat cancer, and further investigate the mechanisms by which IL-6 induces tumor immunosuppression. In clinical samples, IL-6 expression was significantly correlated with α-smooth muscle actin expression, and high IL-6 cases showed tumor immunosuppression. Multivariate analysis showed that IL-6 expression was an independent prognostic factor. In vitro, IL-6 contributed to cell proliferation and differentiation into CAFs. Moreover, IL-6 increased hypoxia-inducible factor 1α (HIF1α) expression and induced tumor immunosuppression by enhancing glucose uptake by cancer cells and competing for glucose with immune cells. MR16-1, a rodent analog of anti-IL-6 receptor antibody, overcame CAF-induced immunosuppression and suppressed tumor progression in immunocompetent murine cancer models by regulating HIF1α activation in vivo. The anti-IL-6 receptor antibody could be systemically employed to overcome tumor immunosuppression and improve patient survival with various cancers. Furthermore, the tumor immunosuppression was suggested to be induced by IL-6 via HIF1α activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer-Associated FibroblastsCarcinoma, Squamous CellAnimalsMiceInterleukin-6Immune ToleranceImmunosuppression TherapyTumor MicroenvironmentCell Line, Tumor

Stichwörter der Autor:innen

Cancer-associated fibroblastsDrug repositioningInterleukin-6 receptor antibodyTumor microenvironment

Substanzen

Interleukin-6

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-Cho, Kita-ku, Okayama, 700-8558, Japan.
  • Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-Cho, Kita-ku, Okayama, 700-8558, Japan. knoma@md.okayama-u.ac.jp.
  • Department of Pathology & Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Department of Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Okayama University

Zitieren

APA

Nishiwaki, N., Noma, K., Ohara, T., Kunitomo, T., Kawasaki, K., Akai, M., Kobayashi, T., Narusaka, T., Kashima, H., Sato, H., Komoto, S., Kato, T., Maeda, N., Kikuchi, S., Tanabe, S., Tazawa, H., Shirakawa, Y., & Fujiwara, T. (2023). Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody. Cancer Immunology, Immunotherapy, 72(7), 2029-2044. https://doi.org/10.1007/s00262-023-03378-7

Vancouver

Nishiwaki N, Noma K, Ohara T, Kunitomo T, Kawasaki K, Akai M, et al. Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody. Cancer Immunology, Immunotherapy. 2023;72(7):2029-2044. doi:10.1007/s00262-023-03378-7

BibTeX
@article{Nishiwaki2023,
  author = {Nishiwaki, Noriyuki and Noma, Kazuhiro and Ohara, Toshiaki and Kunitomo, Tomoyoshi and Kawasaki, Kento and Akai, Masaaki and Kobayashi, Teruki and Narusaka, Toru and Kashima, Hajime and Sato, Hiroaki and Komoto, Satoshi and Kato, Takuya and Maeda, Naoaki and Kikuchi, Satoru and Tanabe, Shunsuke and Tazawa, Hiroshi and Shirakawa, Yasuhiro and Fujiwara, Toshiyoshi},
  title = {Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  volume = {72},
  number = {7},
  pages = {2029--2044},
  doi = {10.1007/s00262-023-03378-7}
}
Kostenlos starten →